Bristol-Myers Squibb And Pfizer To Present New Analyses Of Eliquis (Apixaban) Clinical And Real-World Data At American College of Cardiology 2017 Scientific Session

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that eight abstracts have been accepted for presentation at the American College of Cardiology (ACC) 66th Annual Scientific Session, taking place March 17-19 in Washington, D.C. In addition to post-hoc analyses from the pivotal Phase 3 ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation) trial, the Bristol-Myers Squibb and Pfizer Alliance will present real-world data analyses that illustrate the Alliance’s ongoing commitment to understanding the use of direct oral anticoagulants, including Eliquis™ (apixaban), in routine clinical practice. This real-world research, part of the global ACROPOLIS™ (Apixaban ExperienCe Through Real-WOrld POpuLatIon Studies) program, aims to complement findings from clinical trials and contribute to the growing body of knowledge around anticoagulation.

Back to news